The intramembrane protease SPPL2a promotes B cell development and controls endosomal traffic by cleavage of the invariant chain

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Janna Schneppenheim - , Kiel University (Author)
  • Ralf Dressel - , University of Göttingen (Author)
  • Susann Hüttl - , Kiel University (Author)
  • Renate Lüllmann-Rauch - , Kiel University (Author)
  • Michael Engelke - , University of Göttingen (Author)
  • Kai Dittmann - , University of Göttingen (Author)
  • Jürgen Wienands - , University of Göttingen (Author)
  • Eeva Liisa Eskelinen - , University of Helsinki (Author)
  • Irm Hermans-Borgmeyer - , University of Hamburg (Author)
  • Regina Fluhrer - , Ludwig Maximilian University of Munich, German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Paul Saftig - , Kiel University (Author)
  • Bernd Schröder - , Institute of Physiological Chemistry, Kiel University (Author)

Abstract

Regulated intramembrane proteolysis is a central cellular process involved in signal transduction and membrane protein turnover. The presenilin homologue signalpeptide- peptidase-like 2a (SPPL2a) has been implicated in the cleavage of type 2 transmembrane proteins. We show that the invariant chain (li, CD74) of the major histocompatability class II complex (MHCII) undergoes intramembrane proteolysis mediated by SPPL2a. B lymphocytes of SPPL2a,-/- mice accumulate an N-terminal fragment (NTF) of CD74, which severely impairs membrane traffic within the endocytic system and leads to an altered response to B cell receptor stimulation, reduced BAFF-R surface expression, and accumulation of MHCII in transitional developmental stage T1 B cells. This results in significant loss of B cell subsets beyond the T1 stage and disrupted humoral immune responses, which can be recovered by additional ablation of CD74. Hence, we provide evidence that regulation of CD74-NTF levels by SPPL2a is indispensable for B cell development and function by maintaining trafficking and integrity of MHCII-containing endosomes, highlighting SPPL2a as a promising pharmacological target for depleting and/or modulating B cells.

Details

Original languageEnglish
Pages (from-to)41-58
Number of pages18
JournalJournal of Experimental Medicine
Volume210
Issue number1
Publication statusPublished - Jan 2013
Peer-reviewedYes

External IDs

PubMed 23267015

Keywords

ASJC Scopus subject areas